These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12029559)

  • 1. Methodology of 99mTc-Nanocoll sentinel node localisation in carcinoma of the breast.
    Bourgeois P; Leduc O; Belgrado JP; Leduc A
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):831-2; author reply 832-3. PubMed ID: 12029559
    [No Abstract]   [Full Text] [Related]  

  • 2. Further optimisation of 99mTc-Nanocoll sentinel node localisation in carcinoma of the breast by improved labelling.
    Gommans GM; van Dongen A; van der Schors TG; Gommans E; Visser JF; Clarijs WW; de Waard JW; van de Bos J; Boer RO
    Eur J Nucl Med; 2001 Oct; 28(10):1450-5. PubMed ID: 11685486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of increased (99m)Tc/(99)Tc ratios on count rates in sentinel node procedures: a randomised study.
    Gommans GM; van der Zant FM; van der Schors TG; van Dongen A; Teule GJ; Clarijs WW; Langenhorst BL; de Waard JW
    Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1231-5. PubMed ID: 12827312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 99mTc Nanocoll: a radiopharmaceutical for sentinel node localisation in breast cancer--in vitro and in vivo results.
    Gommans GM; Gommans E; van der Zant FM; Teule GJ; van der Schors TG; de Waard JW
    Appl Radiat Isot; 2009 Sep; 67(9):1550-8. PubMed ID: 19328701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimisation of 99mTc-Nanocoll sentinel node localisation in carcinoma of the breast.
    Gommans GM; Boer RO; van Dongen A; van der Schors TG; de Waard JW
    Eur J Nucl Med; 2000 Jun; 27(6):744. PubMed ID: 10901463
    [No Abstract]   [Full Text] [Related]  

  • 6. An original approach in the diagnosis of early breast cancer: use of the same radiopharmaceutical for both non-palpable lesions and sentinel node localisation.
    Feggi L; Basaglia E; Corcione S; Querzoli P; Soliani G; Ascanelli S; Prandini N; Bergossi L; Carcoforo P
    Eur J Nucl Med; 2001 Nov; 28(11):1589-96. PubMed ID: 11702098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of increased 99mTc/99Tc ratios on count rates in sentinel node procedures: a randomised study.
    Ballinger JR
    Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):306. PubMed ID: 15129717
    [No Abstract]   [Full Text] [Related]  

  • 8. Subareolar injection of technetium-99m nanocolloid yields reliable data on the axillary lymph node tumour status in breast cancer patients with previous manipulations on the primary tumour: a prospective study of 117 patients.
    Maza S; Thomas A; Winzer KJ; Hüttner C; Blohmer JU; Hauschild M; Richter M; Krössin T; Geworski L; Zander A; Guski H; Munz DL
    Eur J Nucl Med Mol Imaging; 2004 May; 31(5):671-5. PubMed ID: 14745517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intratumoral versus subareolar injection in breast cancer sentinel lymph node biopsy. A case report].
    Lanchas Alfonso I; Miguel Martínez MB; CuezvaGuzmán JF; Rupérez Arribas P; Martínez Blanco S; Yartu San Millán JM; Duque Gallo JJ
    Rev Esp Med Nucl; 2011; 30(3):171-3. PubMed ID: 21342723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimised nuclear medicine method for tumour marking and sentinel node detection in occult primary breast lesions.
    De Cicco C; Trifirò G; Intra M; Marotta G; Ciprian A; Frasson A; Prisco G; Luini A; Viale G; Paganelli G
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):349-54. PubMed ID: 14647985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer, Poland's syndrome, and sentinel lymph node involvement.
    Uña J; Vega V; Gutierrez I; Herrera J; Hernández-Briz MJ
    Clin Nucl Med; 2007 Aug; 32(8):613-5. PubMed ID: 17667433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Subareolar injection: a potential cause of false negative in the selective biopsy of the sentinel node in breast cancer].
    Rioja Martín ME; Ortega Pérez G; Cabañas Montero LJ; Muñoz-Madero V; Cabañas Navarro L
    Rev Esp Med Nucl; 2011; 30(4):251-3. PubMed ID: 21440959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 220 patients.
    Sanjuàn A; Vidal-Sicart S; Zanón G; Pahisa J; Velasco M; Fernández PL; Santamaría G; Farrús B; Muñoz M; Albanell J; Pons F; Vanrell JA
    Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):932-6. PubMed ID: 15791433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel lymph node identification with radiopharmaceuticals in patients with breast cancer: a comparison of 99mTc-tin colloid and 99mTc-phytate efficiency.
    Seok JW; Choi YS; Chong S; Kwon GY; Chung YJ; Kim BG; Park SJ
    Breast Cancer Res Treat; 2010 Jul; 122(2):453-7. PubMed ID: 20532977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel nodes outside level I-II of the axilla and staging in breast cancer.
    Rönka R; Krogerus L; Leppänen E; Smitten KV; Leidenius M
    Anticancer Res; 2002; 22(5):3109-12. PubMed ID: 12530052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [False positive of intramammary sentinel node].
    Fuertes J; Mestre-Fusco A; Suárez M; Plancarte F; Munné-Collado J; Vidal-Sicart S
    Rev Esp Med Nucl; 2011; 30(2):112-3. PubMed ID: 21354661
    [No Abstract]   [Full Text] [Related]  

  • 17. [Preliminary study on a new sentinel lymphoscintigraphy agent 99mTc-Rituximab for breast patient].
    Wang XJ; Lin BH; Yang Z; Ouyang T; Li JF; Xu B; Zhang Y; Zhang MY
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):200-3. PubMed ID: 16875605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. False positive of intramammary sentinel lymph node in lymphoscintigraphy.
    Lanchas Alfonso I; Miguel Martínez MB; García Higuera MI; Montero Ruiz JB; Aragón Martinez J; Duque Gallo JJ
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):161-2. PubMed ID: 21944192
    [No Abstract]   [Full Text] [Related]  

  • 19. Grade 3 anaphylactic shock after administration of [
    Skanjeti A; Darcissac C; Jaulent C; Nicolas J; Hallouard F; Morelec I; Fraysse M; Tordo J; Giammarile F; Bolze PA; Dhomps A
    Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1214-1215. PubMed ID: 30879123
    [No Abstract]   [Full Text] [Related]  

  • 20. Periareolar injections and hot sentinel nodes.
    Kim CK; Krynyckyi BR; Machac J; Pelosi E; Bisi G
    J Nucl Med; 2004 Sep; 45(9):1597-9; author reply 1599. PubMed ID: 15347731
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.